《本地樓市》日出康城「凱柏峰III」上載樓書 料短期開價
由信和置業(00083.HK)、嘉華國際(00173.HK)及招商局置地(00978.HK)及港鐵(00066.HK)合作發展的將軍澳日出康城「凱柏峰III」,昨晚(14日)上載樓書至一手住宅物業銷售資訊網,可能短期內公布首張價單。
信和指,項目提供644伙,主打一房及兩房單位,系內首次推出開放式單位,實用面積由283至978平方呎,面積最細為3A座、9至67樓的E室,是實用面積283平方呎的開放式單位。面積最大為3B座67樓頂層特色戶,實用面積978平方呎,三房連平台,內設樓梯通往天台。
項目不設住客停車位,設有24小時通道,住戶可經商場通往港鐵康城站。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.